RxDoctor Payments Data

Daniel Tavari, DO

Family Medicine · Thousand Oaks, CANPI 1942240213

Payments from drug & device makers

$9,892in general payments, 2019–2025

Across 521 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$2K
  • Pfizer$484
  • Astellas Pharma US Inc$431
  • Novartis$382
  • Johnson & Johnson$370
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$9,68798%
  • Education$2052%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)133$2,368
Amgen(2 entities)75$1,685
Pfizer31$484
Astellas Pharma US Inc13$431
Novartis19$382
Johnson & Johnson(2 entities)30$370
Abbott14$332
Merck16$291
GSK14$256
Otsuka America Pharmaceutical, Inc.10$193
Lilly USA, LLC11$189
Novo Nordisk11$158
Radius Health, Inc.8$156
Grifols USA, LLC5$150
Medtronic(2 entities)2$118
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$116
Takeda Pharmaceuticals U.S.A., Inc.9$111
AstraZeneca6$100
Teva Pharmaceuticals USA, Inc.6$98
Amarin Pharma, Inc.5$96
Lundbeck LLC4$89
Regeneron Healthcare Solutions, Inc.4$87
E.r. Squibb & Sons, L.L.C.4$84
Kowa Pharmaceuticals America, Inc.4$77
Genentech USA, Inc.5$76
Corcept Therapeutics3$69
Exact Sciences4$63
Hologic Sales And Service, LLC3$59
Aimmune Therapeutics, Inc.2$56
Nevro Corp.2$56
Bayer3$56
Phathom Pharmaceuticals, Inc.4$51
Alnylam Pharmaceuticals Inc.3$51
Boehringer Ingelheim3$50
Vertiflex, Inc.3$50
Esperion Therapeutics, Inc.2$48
SK Life Science, Inc.2$45
Phadia US Inc.2$42
Almatica Pharma LLC2$41
Boston Scientific2$41
Idorsia Pharmaceuticals US Inc2$40
Sunovion Pharmaceuticals Inc.2$37
Neurocrine Biosciences, Inc.1$35
Eisai Inc.2$32
Sanofi Pasteur Inc.2$32
Sun Pharmaceutical Industries Inc.2$30
Neos Therapeutics, LP2$30
Azurity Pharmaceuticals, Inc.1$29
Merit Medical Systems Inc1$26
Acadia Pharmaceuticals Inc1$24
Nestle Healthcare Nutrition Inc.1$24
Shield Therapeutics Inc1$22
Assertio Therapeutics, Inc.1$22
Duchesnay USA Incorporated1$21
Arbor Pharmaceuticals, Inc.1$21
Angiodynamics, Inc.1$20
Endogastric Solutions, Inc2$19
BD1$18
Sanofi-aventis U.S. LLC1$17
Acerus Pharmaceuticals Corporation1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,892 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$946,563
Medicare patients
1,021
Services billed
20,243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban262$138,379
OzempicSemaglutide69$85,794
NuplazidPimavanserin Tartrate13$67,045
XareltoRivaroxaban104$64,968
JanuviaSitagliptin Phosphate87$51,829
JardianceEmpagliflozin61$48,882
TrulicityDulaglutide28$43,159
MyrbetriqMirabegron47$23,272
MounjaroTirzepatide16$23,241
TradjentaLinagliptin36$18,822
LinzessLinaclotide18$14,812
ArexvyRsvpref3 Antigen/As01e/Pf44$13,464
OxycontinOxycodone Hcl13$12,503
VascepaIcosapent Ethyl17$11,979
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$484$138,379262 claims
Novo NordiskOzempic$158$85,79469 claims
Boehringer IngelheimJardiance, Tradjenta$50$67,70497 claims
Acadia Pharmaceuticals IncNuplazid$24$67,04513 claims
Lilly USA, LLCTrulicity, Mounjaro$189$66,39944 claims
Johnson & JohnsonXarelto$370$64,968104 claims
MerckJanuvia$291$51,82987 claims
GSKArexvy, Trelegy Ellipta, Breo Ellipta, Shingrix$256$40,341112 claims
Astellas Pharma US IncMyrbetriq$431$23,27247 claims
AbbVieLinzess$2,368$14,81218 claims
AstraZenecaFarxiga$100$10,45414 claims
NovartisEntresto$382$5,01612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Thousand Oaks

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →